NEW YORK (GenomeWeb News) – Cellumen said today that it has entered into a research collaboration with the National Center for Toxicological Research, part of the US Food and Drug Administration, to test known liver toxicity drugs.
Cellumen will use its CellCiphr cell-based assay to create profiles of blinded samples of these compounds from failed and marketed drugs, and the NCTR will incorporate information about these drugs into a liver toxicity knowledge database.
The company said that its profiling technology can be used by drug companies to identify “compounds with high human toxic liabilities,” allowing drug companies to take actions or to measure the risk of certain compounds.
Cellumen also said it plans to use the profiling and safety data from the collaboration to continue to develop the CellCiphr database, cell panels, and informatics tools.